Cognitive Research Enterprises, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
Mar 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 18, 2026The maintenance fee for Pkc-Activating Compounds for the Treatment of Neurodegenerative Diseases (US 10,323,011) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due Mar 1, 2027The maintenance fee for Pkc-Activating Compounds for the Treatment of Neurodegenerative Diseases (US 9,119,825) comes due Mar 1, 2027. Unpaid by Sep 1, 2027, it lapses early.
- 1 fee due Apr 20, 2027The maintenance fee for Esters of DCPLA and methods of treatment using the same (US 9,163,032) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,974,832 | Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury In force · From the USPTO record | In force | From the USPTO record | |
| US 9,119,825 | Pkc-Activating Compounds for the Treatment of Neurodegenerative Diseases In force · High confidence | In force | High confidence | |
| US 10,323,011 | Pkc-Activating Compounds for the Treatment of Neurodegenerative Diseases In force · High confidence | In force | High confidence | |
| US 10,696,644 | Pkc-Activating Compounds for the Treatment of Neurodegenerative Diseases In force · High confidence | In force | High confidence | |
| US 8,163,800 | Pkc-Activating Compounds for the Treatment of Neurodegenerative Diseases In force · High confidence | In force | High confidence | |
| US 9,163,032 | Esters of DCPLA and methods of treatment using the same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,597,312 | Treatment of cognitive disorders associated with abnormal dendritic spines using PKC activators In force · From the USPTO record | In force | From the USPTO record | |
| US 10,821,079 | PKC activators and combinations thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,833,435 | Compositions and methods to treat Niemann-Pick disease In force · From the USPTO record | In force | From the USPTO record | |
| US 10,137,106 | Compositions and methods to treat niemann-pick disease In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 11: 1 lapsed for an unpaid fee · 5 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 no status recorded